公开(公告)号：WO2012131710A3

公开(公告)日：2012-10-04

申请号：PCT/IN2012/000201

申请日：2012-03-27

Applicant: PANACEA BIOTEC LTD ,  JAIN, Rajesh ,  RAO, Jagadeeshwar R ,  RAO, Siripragada Mahender

Inventor： JAIN, Rajesh ,  RAO, Jagadeeshwar R ,  RAO, Siripragada Mahender

IPC: C07D209/08

Abstract: The present invention provides a process for the synthesis of indoline intermidiate useful in the synthesis of α-1 adrenoceptor blockers such as silodosin. Indoline intermediate has following formula: (where R is hydroxy or protecting group) and is preferably a tartrate salt.

公开(公告)号：WO2010106557A3

公开(公告)日：2011-03-10

申请号：PCT/IN2010000163

申请日：2010-03-19

Applicant: PANACEA BIOTEC LTD ,  JAIN RAJESH ,  SINGH SARABJIT ,  SINGH PARAMJIT ,  SINGH PIRTHI PAL

Inventor： JAIN RAJESH ,  SINGH SARABJIT ,  SINGH PARAMJIT ,  SINGH PIRTHI PAL

IPC: A01N59/16 ,  A61K33/24

CPC classification number: A61K33/24 ,  A61K9/0056 ,  A61K9/2054

Abstract: The present invention discloses the premix pharmaceutical formulation comprising anhydrous lanthanum carbonate. The present invention further relates to a stable pharmaceutical formulation comprising a therapeutically effective amount of anhydrous lanthanum carbonate and pharmaceutically acceptable carrier and/or excipients, with the proviso that the said formulation is substantially free of monosaccharides or disaccharides. Further the said formulation is substantially free of amino acids and/or stabilizers. The process of preparing such formulations is also described.

Abstract translation: 本发明公开了包含无水碳酸镧的预混药物制剂。 本发明还涉及包含治疗有效量的无水碳酸镧和药学上可接受的载体和/或赋形剂的稳定药物制剂，条件是所述制剂基本上不含单糖或二糖。 此外，所述制剂基本上不含氨基酸和/或稳定剂。 还描述了制备这种制剂的方法。

公开(公告)号：WO2010134094A9

公开(公告)日：2011-02-03

申请号：PCT/IN2010000314

申请日：2010-05-17

Applicant: PANACEA BIOTEC LTD ,  JAIN RAJESH ,  VINAYAK VIRENDER KUMAR ,  SHUKLA NIDHI ,  AGGARWAL NEERAJ ,  MEHTA RAJAN

Inventor： JAIN RAJESH ,  VINAYAK VIRENDER KUMAR ,  SHUKLA NIDHI ,  AGGARWAL NEERAJ ,  MEHTA RAJAN

IPC: A61K39/145

CPC classification number: A61K39/145 ,  A61K39/12 ,  A61K2039/5256 ,  C12N2710/24143 ,  C12N2760/16134

Abstract: The present invention relates to a novel influenza vaccine, a novel plasmid for preparing the same and a novel dosage form comprising the same. The present invention in particular relates to a recombinant modified vaccinia Ankara (MVA) virus comprising and capable of simultaneously expressing a cassette of at least four foreign genes from influenza virus, specifically an avian influenza virus, wherein the said genes are inserted at a non-essential site, within the MVA genome. The invention further relates to a recombinant modified vaccinia Ankara (MVA) virus comprising and capable of simultaneously expressing a cassette of not less than two foreign genes from influenza virus, wherein the said genes are inserted at a non-essential site, within the MVA genome, with the provision that at least one foreign gene is either PB2 or M2e. The invention also provides composition and methods of making the universal influenza vaccine.

Abstract translation: 本发明涉及新型流感疫苗，其制备新颖的质粒和含有该新颖剂型。 本发明特别涉及重组修饰的痘苗安卡拉（MVA）病毒，其包含并能够同时表达来自流感病毒，特别是禽流感病毒的至少四种外来基因的盒，其中所述基因以非 - 必需部位，在MVA基因组内。 本发明还涉及重组修饰的痘苗安卡拉（MVA）病毒，其包含并能够同时表达来自流感病毒的不少于两个外来基因的盒，其中所述基因插入在MVA基因组内的非必需位点 规定至少一个外来基因是PB2或M2e。 本发明还提供制备普通流感疫苗的组合物和方法。

公开(公告)号：WO2010150281A2

公开(公告)日：2010-12-29

申请号：PCT/IN2010/000428

申请日：2010-06-22

Applicant: PANACEA BIOTEC LTD. ,  JAIN, Rajesh ,  TREHAN, Sanjay ,  DAS, Jagattaran ,  KAUR, Gurmeet ,  KANWAR, Sandeep ,  SINGH, Nishan ,  NANDA, Gurmeet Kaur ,  MAGADI, Sitaram Kumar ,  SHARMA, Sudhir Kumar

Inventor： JAIN, Rajesh ,  TREHAN, Sanjay ,  DAS, Jagattaran ,  KAUR, Gurmeet ,  KANWAR, Sandeep ,  SINGH, Nishan ,  NANDA, Gurmeet Kaur ,  MAGADI, Sitaram Kumar ,  SHARMA, Sudhir Kumar

IPC: C07D221/22 ,  C07D401/10 ,  C07D413/10 ,  C07D413/14 ,  C07D417/10 ,  C07D471/04 ,  C07D491/08 ,  A61K31/46 ,  A61K31/496 ,  A61K31/498 ,  A61K31/5355 ,  A61K31/551 ,  C07D487/04 ,  A61P25/00 ,  A61P31/00

CPC classification number: C07D221/22 ,  C07D209/52 ,  C07D401/10 ,  C07D409/04 ,  C07D413/10 ,  C07D413/14 ,  C07D417/10 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  C07D491/08

Abstract: The present invention relates to novel compounds of Formula (I), their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers including R and S isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers, polymorphs, prodrugs, metabolites, salts or solvates thereof.

Abstract translation: 本发明涉及式（I）的新化合物，其药学上可接受的衍生物，互变异构体，立体异构体，包括R和S异构体，多晶型物，前药，代谢物，盐或溶剂化物。 本发明还涉及合成式I的新化合物，其药学上可接受的衍生物，互变异构体形式，立体异构体，多晶型物，前药，代谢物，盐或溶剂合物的方法。

公开(公告)号：WO2010137036A2

公开(公告)日：2010-12-02

申请号：PCT/IN2010/000343

申请日：2010-05-21

Applicant: PANACEA BIOTEC LTD ,  JAIN, Rajesh ,  GALGALKAR, Milind V ,  MAITHAL, Kapil ,  VRATI, Sudhanshu

Inventor： JAIN, Rajesh ,  GALGALKAR, Milind V ,  MAITHAL, Kapil ,  VRATI, Sudhanshu

IPC: A61K39/12

CPC classification number: C12N7/00 ,  A61K39/12 ,  A61K2039/5252 ,  A61K2039/55505 ,  C12N2770/24134 ,  C12N2770/24151 ,  C12N2770/24163 ,  Y02A50/39

Abstract: The present invention relates to a novel Japanese encephalitis vaccine and a novel process for making the same. The invention in particular relates to a Japanese encephalitis virus strain P20778 vaccine, wherein the viral adaptation and propagation is carried out in a medium which is free of serum and additives of animal origin. The virus may be propagated particularly in Vero cell line.

Abstract translation: 本发明涉及一种新型的日本脑炎疫苗及其制造方法。 本发明特别涉及日本脑炎病毒株P20778疫苗，其中病毒适应和繁殖在不含血清和动物来源的添加剂的培养基中进行。 病毒可能在Vero细胞系中特别传播。

公开(公告)号：WO2010082214A2

公开(公告)日：2010-07-22

申请号：PCT/IN2009000365

申请日：2009-06-26

Applicant: PANACEA BIOTEC LTD ,  JAIN RAJESH ,  SINGH SARABJIT ,  JAIN NAVEEN ,  PUTHLI SHIVANAND

Inventor： JAIN RAJESH ,  SINGH SARABJIT ,  JAIN NAVEEN ,  PUTHLI SHIVANAND

IPC: A61K9/48 ,  A61K31/216

CPC classification number: A61K9/4858

Abstract: The present invention provides a formulation of fenofibrate with enhanced oral bioavailability, simplicity of design and manufacture and absence of food effect. The formulation comprises fenofibrate dissolved in a lipophilic surfactant, with a hydrophilic surfactant optionally added. The formulation can be effectively used in the management and treatment of conditions such as hypertriglyceridemia, hypercholesterolemia and mixed dyslipidemia, and can also be effective at lower doses as compared to commercially available products. The invention additionally relates to the process of manufacture of the formulation and to dosage forms comprising the same.

Abstract translation: 本发明提供了非诺贝特的制剂，其具有增强的口服生物利用度，设计和制造的简单性和食物效果的不存在。 该制剂包含溶解在亲脂性表面活性剂中的非诺贝特，任选加入亲水性表面活性剂。 该制剂可以有效地用于治疗和治疗诸如高甘油三酯血症，高胆固醇血症和混合性血脂异常的病症，并且与可商购的产品相比也可以以较低的剂量有效。 本发明还涉及制剂的制备方法和包含其的剂型。

公开(公告)号：WO2009060473A3

公开(公告)日：2009-10-15

申请号：PCT/IN2008000757

申请日：2008-11-06

Applicant: PANACEA BIOTEC LTD ,  JAIN RAJESH ,  SINGH SUKHJEET ,  DEVARAJAN SAMPATH KUMAR

Inventor： JAIN RAJESH ,  SINGH SUKHJEET ,  DEVARAJAN SAMPATH KUMAR

IPC: A61K9/08 ,  A61K9/10 ,  A61K47/34

CPC classification number: A61K9/0024 ,  A61K9/06

Abstract: Injectable depot gel or implant compositions comprising at least one active agent(s) selected from a group comprising antipsychotics, aromatase inhibitors, alpha-1 adrenergic blocking agents, acetylcholinesterase inhibitors, and pharmaceutically acceptable salts, derivatives, isomers, polymorphs, solvates, hydrates, analogues, enantiomers, tautomeric forms or mixtures thereof; at least one biocompatible bioerodible polymer(s); at least one biocompatible non-toxic solvent(s) and optionally one or more pharmaceutically acceptable excipient(s) are provided. The present invention also describes process for preparation of such compositions and method of using such compositions.

Abstract translation: 包含至少一种选自抗精神病药，芳香酶抑制剂，α-1肾上腺素能阻断剂，乙酰胆碱酯酶抑制剂及其药学上可接受的盐，衍生物，异构体，多晶型物，溶剂合物，水合物， 类似物，对映异构体，互变异构形式或其混合物; 至少一种生物相容性生物可蚀解聚合物; 提供至少一种生物相容性无毒溶剂和任选的一种或多种药学上可接受的赋形剂。 本发明还描述了用于制备这种组合物的方法和使用这种组合物的方法。

公开(公告)号：WO2009050726A3

公开(公告)日：2009-06-25

申请号：PCT/IN2008000337

申请日：2008-05-28

Applicant: PANACEA BIOTEC LTD ,  SINGH AMARJIT ,  SINGH SARABJIT ,  PRASAD KORLAKUNTE ,  JAIN RAJESH

Inventor： SINGH AMARJIT ,  SINGH SARABJIT ,  PRASAD KORLAKUNTE ,  JAIN RAJESH

IPC: A61K9/50 ,  A61K9/16 ,  A61K31/137

CPC classification number: A61K31/137 ,  A61K9/0043 ,  A61K9/141 ,  A61K9/48 ,  A61K9/5021

Abstract: The present invention provides a pharmaceutical composition comprising micronized bupropion having controlled particle size in the range between 1-60 µm. The pharmaceutical composition of the present invention comprises micronized bupropion having median particle size less than 40 micron, which exhibits outstanding bioavailability via nasal and pulmonary route even without any need for blending the micronized bupropion with large carrier particles. The composition of the present invention comprises micronized bupropion -and one or more pharmaceutically acceptable carriers, surfactants, a dispersing agents, or dispersants, which can be administered in an aerosol formulation as a dry powder for nasal and pulmonary inhalation. Particularly, the composition of the present invention for nasal delivery comprises bioadhesive microparticles of bupropion and carbohydrates like pullulan to prevent and treat diseases such as depression, premenstrual syndrome, premature ejaculation and as an aid to smoking cessation. The invention also provides a process of preparing the compositions of the present invention.

Abstract translation: 本发明提供一种药物组合物，其包含微粒化的安非他酮，其控制粒度在1-60μm之间。 本发明的药物组合物包含中值粒度小于40微米的微粉化安非他酮，即使不需要将微粉化的安非他酮与大载体颗粒混合，也可以通过鼻和肺途径表现出优异的生物利用度。 本发明的组合物包含微粉化的安非他酮和一种或多种药学上可接受的载体，表面活性剂，分散剂或分散剂，其可以作为用于鼻吸入和肺部吸入的干粉在气溶胶制剂中施用。 特别地，用于鼻腔输送的本发明的组合物包括安非他酮的生物粘附微粒和诸如支链淀粉的碳水化合物，以预防和治疗诸如抑郁症，经前期综合征，早泄以及作为戒烟的辅助之类的疾病。 本发明还提供了制备本发明组合物的方法。

公开(公告)号：WO2007125545A3

公开(公告)日：2008-02-21

申请号：PCT/IN2007000164

申请日：2007-04-25

Applicant: PANACEA BIOTEC LTD ,  SINGH AMARJIT ,  SINGH SARABJIT ,  PUTHLI SHIVANAND

Inventor： SINGH AMARJIT ,  SINGH SARABJIT ,  PUTHLI SHIVANAND

IPC: A61K47/38 ,  A61K9/70 ,  A61K47/32 ,  A61M37/00

CPC classification number: A61K9/0056 ,  A61K9/006 ,  A61K9/2072 ,  A61K9/2086

Abstract: The invention provides a composition for delivering active agents through transmucosal administration, more particularly through the buccal mucosa. The composition is a unique transmucosal disk (10) which has two compartments (14) and (18); the compartments consist of at least one active agent and at least one mucoadhesive agent and both the compartments are adapted to be in contact with the mucosal membrane. The invention also provides for transmucosal administration of an active agent and method of treatment of diseases in a subject in need of such treatment.

Abstract translation: 本发明提供了一种用于通过经粘膜给药递送活性剂的组合物，更具体地通过颊粘膜递送。 该组合物是独特的经粘膜盘（10），其具有两个隔间（14）和（18）; 隔室由至少一种活性剂和至少一种粘膜粘附剂组成，并且两个隔室都适于与粘膜接触。 本发明还提供活性剂的经粘膜给药和治疗需要这种治疗的受试者的疾病的方法。

公开(公告)号：WO2007086078A3

公开(公告)日：2007-12-13

申请号：PCT/IN2007000029

申请日：2007-01-29

Applicant: PANACEA BIOTEC LTD ,  JAIN RAJESH ,  JINDAL KOUR CHAND ,  DEVARAJAN SAMPATH KUMAR

Inventor： JAIN RAJESH ,  JINDAL KOUR CHAND ,  DEVARAJAN SAMPATH KUMAR

IPC: A61K9/24 ,  A61K9/26 ,  A61K9/48

CPC classification number: A61K9/2081 ,  A61K9/0065 ,  A61K9/2077 ,  A61K9/209 ,  A61K9/485 ,  A61K9/4858 ,  A61K9/4866 ,  A61K9/5026 ,  A61K9/5036

Abstract: Novel pharmaceutical compositions comprising at least one active agent(s) or its pharmaceutically acceptable salts, polymorphs, solvates, hydrates, analogues, enantiomers, tautomeric forms or mixtures thereof; at least one permeation enhancer(s); at least one adsorbent(s) and at least one bioadhesive polymer(s); optionally at least one acid soluble polymer(s) and optionally one or more other pharmaceutically acceptable excipient(s) are provided. Preferably the compositions are in the gastro-adhesive modified release form and/or fast disintegrating dosage form which release the active agent(s) over an extended period of time. Also provided are processes of preparation of such novel compositions and methods of using them.

Abstract translation: 新颖的药物组合物，其包含至少一种活性剂或其药学上可接受的盐，多晶型物，溶剂化物，水合物，类似物，对映异构体，互变异构形式或其混合物; 至少一种渗透促进剂; 至少一种吸附剂和至少一种生物粘附聚合物; 任选地提供至少一种酸溶性聚合物和任选的一种或多种其他药学上可接受的赋形剂。 优选地，组合物处于胃粘附改进释放形式和/或快速崩解剂型，其在一段延长的时间内释放活性剂。 还提供了这种新型组合物的制备方法和使用它们的方法。